Biotech | 25 January 2023
CrisprBits develops CRISPR-based SARS-CoV2 test OmiCrisp
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
The plant, to be built in the Incheon Free Economic Zone in Songdo, Incheon, will be a facility for the manufacture of products such as sterile bags, cell culture media and membrane filters
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
The company will reduce wastage substantially, increase productivity, enhance environmental consciousness, save energy, optimally use natural resources, and expand its market penetration
Strand’s new offering will help people better understand and manage diseases through genomic sequencing
UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
Two main objectives are: Accelerate novel technologies and products for global markets; and Connect academia and industry, creating synergy for faster advancement of the Bioprotection sector
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Collaboration supports multiple discovery efforts, including vaccines
Company appoints five new independent directors to reconstituted board
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
Advancing to IND-enabling studies with multiple drug candidates
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
